The Biggest Thing in AI Right Now (and How to Play It)

The Biggest Thing in AI Right Now (and How to Play It)

Chris Wood’s microcap stocks are scorching hot.

Even with the recent market volatility, his premium Project 5X portfolio is showing an average gain of 85% across 13 open positions as I type.

On Monday, Chris explained how he pinpoints big winners time and time again… gains that make Bitcoin’s recent returns look small.

And from the feedback on that conversation… it’s clear you want to hear more on this explosive class of stocks.

So I caught up with Chris again to see a) where the biggest opportunity is in the space right now… and b) what readers can do today to take advantage.

***

CR: Hey Chris, last time we talked, you shared a couple key reasons why “the right” microcaps can produce very large returns in short periods of time. Like the 422%, 399%, and 376% returns your picks have achieved recently...

Today, I’m hoping you can elaborate on which microcaps are “the right” ones to own today for 500% or better gains...

Chris Wood: Sure. I focus on “early-stage” microcaps disrupting today’s most important tech industries.

I’ve found they give you the best shot, hands down, at 5X-ing your money.

CR: And what industries are you focused on today? 5G? Streaming technology? Augmented reality? Artificial intelligence?

Chris Wood: Big profits are up for grabs in all of those sectors.

But for me, Artificial intelligence (AI) is #1, hands down.

And I’ll go a step further... there’s one small subsector of AI, unknown to most investors, that has the potential to hand out bigger returns than any other asset class in 2021. Bigger even than Bitcoin...

CR: I see… so what’s this AI subsector?

Chris Wood: By far, the biggest thing in AI today isn’t in cybersecurity… manufacturing… or even ecommerce.

It’s AI in drug development.

Although AI in drug development has been around for years, it’s only just now starting to get the attention it deserves.

Just check out these recent headlines:

Fortune: Medicine by machine: “Is A.I. the cure for the world’s ailing drug industry?”

Scientific American: “Hunting for New Drugs with AI”

Forbes: “Transforming Drug Discovery Through Artificial Intelligence”

Meanwhile, there are 230 startups that I know of using AI in drug development. And venture capital investment for AI in drug development reached a whopping $5.2 billion in 2019.

CR: It sounds big. Can you explain how AI enhances drug development?

Chris Wood: So, the old way of developing drugs suffers from a major problem.

In short, it’s incredibly hard to make a new drug and bring it to market.

It takes a long time. It’s expensive. And it’s very, very risky.

For example:

  • It takes 10 to 15 years on average to get a new drug candidate from the lab to pharmacy shelves.
  • It costs up to several billion dollars.
  • And only about 1 in 10 drug candidates ends up receiving FDA approval.

Slow, inefficient, and expensive...

In other words, drug development is begging to be disrupted.

That’s where AI comes in. It’s disrupting the colossal $140 billion cancer drug market.

In short, AI can help companies develop drugs cheaper, faster, better, and with greater precision and less risk.

And in doing so, it literally saves lives...

CR: How so?

Chris Wood: I’ve been analyzing and investing in biotech microcaps for more than a decade. And in that time, I can’t tell you how many promising drugs I’ve come across that failed in the final phase of their trials—just before they got over the “finish line.”

It happens most frequently with cancer drugs, unfortunately. From 2001 through 2015, just 35.5% of Phase 3 (the final phase) cancer drugs ended up receiving FDA approval. That was by far the lowest success rate of any therapeutic area.

CR: So what’s going on? Why do all these cancer drugs fail in the final phase?

Chris Wood: The simple answer is that these drugs work in some patients, but not in all patients.

See, cancer isn’t just one disease. It’s a collection of hundreds of diseases. Each cancer has unique characteristics and its own genomic profile.

For example, we used to think of lung cancer as a single disease. But now we categorize it into at least 12 distinct subtypes based on the genetic mutations that drive its growth.

So if you run a big clinical trial evaluating a drug in all lung cancer patients, it is set up to fail.

Even if it is 100% effective against 1 of those 12 subtypes.

What this means is that many cancer drugs fail in Phase 3, not because they’re bad drugs, but because they weren’t targeted to the right patients.

CR: So which microcaps are solving this big problem?

Chris Wood: Not “microcaps.” Microcap.

There’s only one microcap on the planet using AI to disrupt cancer drug development.

Its tech has been validated in blind case studies with over 80% accuracy.

Meanwhile, the company already has three drugs in development.

It has locked down 80 patents.

And it is collaborating with prestigious cancer institutions including Memorial Sloan Kettering Cancer Center, the National Cancer Institute, and Georgetown University.

CR: It sounds like it’s the real deal…

Chris Wood: It is. Get this: It successfully got its prostate cancer drug into Phase 2 trials 10 times faster than the average drug takes.

And for 50 times cheaper!

It's all thanks to its proprietary AI... which analyzes more than 1 billion data points to select the right patients to include in the right trials.

That’s the whole key. At the end of the day, a drug is a tool.

Like any tool, if you use it to do the wrong job, it won’t work. You don’t drive a screw into wood with a hammer.

This microcap’s AI matches up a drug with the correct patient population more effectively than any other method on the planet, as far as I’m aware. It matches the right tools (drugs) with the right jobs (patients with different types of cancer).

In a nutshell, that’s why it’s a total game-changer.

CR: That’s exciting. One last question... On Monday, you showed us how important it is to meet the CEOs behind the companies you recommend. Were you able to do that for this one?

Chris Wood: I’m glad you brought that up… Because there’s something I forgot to mention on Monday…

I want my subscribers to be able to meet the management teams behind these great companies as well. And ask them any questions they may have about the stock.

So, I try to set up frequent Q&A sessions, exclusively for my Project 5X readers only, with the CEOs behind these microcaps. These sessions are very popular with my readers.

So to answer your question, yes… I’ve been in close contact with the CEO of this company all along, and I’ve already scheduled another call with him later this month. My readers can join in like usual with through a Zoom video link.

CR: If you’d like to get in on this microcap—the only one on the planet using AI to develop cancer drugs—we have good news…

Chris just released a brand-new briefing on this stock, including how to buy it today to lock in potential profits of more than 900%.

And with 4 important milestones coming up in 2021, including one as early as this month, those profits could start rolling in any day now.

Learn how to get all the details on this microcap here.

Chris Reilly
Executive Editor, RiskHedge